The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved treatment for many recurrent or metastatic SCCHN patients, most patients still relapse and ultimately die of their disease. Owing to the high levels of unmet need for more-efficacious and better-tolerated therapies, significant commercial opportunity remains.
The “Unmet Need” module provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in recurrent or metastatic SCCHN. We analyze the commercial opportunities in this market and how emerging therapies may capitalize on these opportunities.